South Korea
· Delayed Price · Currency is KRW Jeonjinbio Statistics
Total Valuation
Jeonjinbio has a market cap or net worth of KRW 24.50 billion. The enterprise value is 21.52 billion.
| Market Cap | 24.50B |
| Enterprise Value | 21.52B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Jeonjinbio has 9.06 million shares outstanding. The number of shares has increased by 12.04% in one year.
| Shares Outstanding | 9.06M |
| Shares Change (YoY) | +12.04% |
| Shares Change (QoQ) | +6.03% |
| Owned by Insiders (%) | 6.84% |
| Owned by Institutions (%) | 3.99% |
| Float | 7.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.10 |
| PB Ratio | 1.35 |
| P/FCF Ratio | 37.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.34, with an EV/FCF ratio of 33.14.
| EV / Earnings | -107.05 |
| EV / Sales | 1.12 |
| EV / EBITDA | 10.34 |
| EV / EBIT | 57.93 |
| EV / FCF | 33.14 |
Financial Position
The company has a current ratio of 3.59, with a Debt / Equity ratio of 3.32.
| Current Ratio | 3.59 |
| Quick Ratio | 2.48 |
| Debt / Equity | 3.32 |
| Debt / EBITDA | 0.27 |
| Debt / FCF | 0.86 |
| Interest Coverage | 0.43 |
Financial Efficiency
Return on equity (ROE) is -1.58% and return on invested capital (ROIC) is 1.46%.
| Return on Equity (ROE) | -1.58% |
| Return on Assets (ROA) | 1.24% |
| Return on Capital (ROIC) | 1.46% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 1.02 |
| Inventory Turnover | 6.20 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.61% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.61% |
| 50-Day Moving Average | 3,159.30 |
| 200-Day Moving Average | 6,289.75 |
| Relative Strength Index (RSI) | 41.99 |
| Average Volume (20 Days) | 199,042 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jeonjinbio had revenue of KRW 19.14 billion and -201.06 million in losses. Loss per share was -25.77.
| Revenue | 19.14B |
| Gross Profit | 6.11B |
| Operating Income | 371.55M |
| Pretax Income | -201.06M |
| Net Income | -201.06M |
| EBITDA | 2.08B |
| EBIT | 371.55M |
| Loss Per Share | -25.77 |
Balance Sheet
The company has 3.54 billion in cash and 559.31 million in debt, giving a net cash position of 2.98 billion or 329.04 per share.
| Cash & Cash Equivalents | 3.54B |
| Total Debt | 559.31M |
| Net Cash | 2.98B |
| Net Cash Per Share | 329.04 |
| Equity (Book Value) | 16.85B |
| Book Value Per Share | 2,010.72 |
| Working Capital | 7.34B |
Cash Flow
In the last 12 months, operating cash flow was 1.39 billion and capital expenditures -742.88 million, giving a free cash flow of 649.53 million.
| Operating Cash Flow | 1.39B |
| Capital Expenditures | -742.88M |
| Free Cash Flow | 649.53M |
| FCF Per Share | 71.70 |
Margins
Gross margin is 31.91%, with operating and profit margins of 1.94% and -1.05%.
| Gross Margin | 31.91% |
| Operating Margin | 1.94% |
| Pretax Margin | -1.05% |
| Profit Margin | -1.05% |
| EBITDA Margin | 10.88% |
| EBIT Margin | 1.94% |
| FCF Margin | 3.39% |
Dividends & Yields
Jeonjinbio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.04% |
| Shareholder Yield | -12.04% |
| Earnings Yield | -0.95% |
| FCF Yield | 2.65% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |